metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1	0.89 [0.76; 1.05], 1 RCT, I2=0% inconclusive result	0.82 [0.69; 0.97], 1 RCT, I2=0% unassessable degree of certainty	-
versus Standard of Care (SoC)
	atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC)	1	0.86 [0.72; 1.02], 1 RCT, I2=0% inconclusive result	0.80 [0.69; 0.92], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
	atezolizumab plus paclitaxel vs. Standard of Care (SoC)	1	1.12 [0.88; 1.43], 1 RCT, I2=0% inconclusive result	0.86 [0.70; 1.05], 1 RCT, I2=0% inconclusive result	-